Skip to main content

Market Overview

Ultragenyx's Dojolvi Ok'd In Canada For Genetic Metabolic Disorder

  • Health Canada approves Ultragenyx Pharmaceutical Inc's (NASDAQ: RARE) Dojolvi (triheptanoin) as a source of calories and fatty acids for the treatment of adult and pediatric patients with long-chain fatty acid oxidation disorders (LC-FAOD).
  • LC-FAOD are a group of rare, genetic, metabolic deficiencies caused by defects in the enzymes needed to produce energy from fatty acids.
  • Dojolvi is a highly purified, synthetic, 7-carbon fatty acid triglyceride specifically designed to provide medium-chain, odd-carbon fatty acids as an energy source and metabolite replacement.
  • The treatment received U.S. approval in July last year.
  • Price Action: RARE stock decreased 1.54% at $142.11 in trading session on last check Wednesday.

Related Articles (RARE)

View Comments and Join the Discussion!

Posted-In: Genetic Metabolic Disorder Health CanadaBiotech News FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at